Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3760)	10/11/1999 1:30:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Here's some news pointed out to me by a friend on the upcoming biggest chiral switch of all - omeprazole (Prilosec/Losec): > Monday October 11, 10:40 am Eastern Time > AstraZeneca to launch Perprazol in Q3 2000 > STOCKHOLM, Oct 11 (Reuters) - Swedish-British drug group > AstraZeneca AZN.L> > will launch Perprazol, the successor to its ulcer drug Losec, in Europe in > the third quarter of 2000 and in the United States in late > 2000/early 2001, > it said on Monday. > > AstraZeneca will file for approval for the new drug in Europe this month, > with a U.S. filing following a few weeks later, Martin Nicklasson, head of > the gastro-intestinal division, told Reuters in an interview. > > ''We expect to launch Perprazol in a dozen countries in Europe > some time in > the third quarter of the year 2000,'' Nicklasson said. > > ''When the launch will be in the United States depends on the > hearings with > the FDA (U.S. Food and Drug Adminstration). But we expect it will be > thoroughly finished in December 2000 or first quarter 2001.'' > > The first clinical tests of Perprazol were presented in October last year > and showed the drug was more effective than Losec in treating > some kinds of > ulcer. The results of the final clinical studies have also been > convincing, > he said. > > ''I am not worried whether Perprazol will keep its promise,'' Niklasson > said. ''We have received very convincing data lately which fortifies us.'' > > AstraZeneca will present the results of the Perprazol study to analysts at > research conferences in London on December 6 and New York on > December 8, and > will also release the name under which it will be marketed. Full clinical > results will be presented for the first time in spring 2000. > All I've been able to find on the study was this one snippet probably from last year - most of the hits on the web are in Swedish: Astra's sequel to Losec, Perprazol, has shown "a significant clinical improvement" compared to Losec in a recent study. Its healing capacity was as much as 15 percent better than Losec when used against refluxesofagit. Astra will apply for approval of Perprazol on the US market in Q3 1999, and somewhat earlier in Europe. (FinansTidningen) I've always been a little skeptical of this class of ICE's, as the underlying drugs are already excellent. However, if they can really show improved results in GERD, then this would pressure Abbott and AHP to license the SEPR ICE's for their drugs (Prevacid and Pantozol). We will also get to see how AZN does in marketing a "somewhat" improved drug against the generic. If they are successful, it will bode very well indeed for SEPR. Peter

To: Vector1 who wrote (3760)	10/12/1999 10:17:00 AM
From: j_fir2	Respond to of 10280

Meanwhile, the competition keeps on keeping on, too: LONG-TERM SALMETEROL USE DOES NOT REDUCE BRONCHIAL PROTECTION IN ASTHMA Long-term therapy with the long-acting beta-agonist salmeterol controls asthma symptoms well without leading to increased bronchial hyperresponsiveness, researchers report in the September issue of Chest. pharmacotherapy.medscape.com <a href="http://pharmacotherapy.medscape.com/12709.rhtml">Read it Here</a> INHALED OLPRINONE SHOWS PROMISE IN ASTHMA TREATMENT Preliminary studies show that inhalation of the newly developed phosphodiesterase (PDE) 3 inhibitor olprinone increases airway caliber in asthmatic patients, Japanese researchers report in the September issue of the American Journal of Respiratory and Critical Care Medicine. pharmacotherapy.medscape.com <a href="http://pharmacotherapy.medscape.com/12755.rhtml">Read it Here</a>